Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2013

Open Access 01-12-2013 | Commentary

Lynch syndrome related endometrial cancer: clinical significance beyond the endometrium

Authors: Yiying Wang, Yue Wang, Jie Li, Janiel Cragun, Kenneth Hatch, Setsuko K Chambers, Wenxin Zheng

Published in: Journal of Hematology & Oncology | Issue 1/2013

Login to get access

Abstract

Lynch syndrome (LS), an autosomal dominant inherited cancer susceptibility syndrome, also known as hereditary non-polyposis colon cancer (HNPCC), is caused by a germline mutation in one of several DNA mismatch repair (MMR) genes. LS is the most common presentation of hereditary colorectal cancer (CRC), accounting for about 2–5% of all CRC cases. More recently, it is found that a similar number of endometrial cancers is also due to one of the MMR gene mutations. There has been significant progress in LS-related CRC in terms of molecular pathogenesis, risks, genetic basis, and cancer prevention. In contrast, the advance about LS-related endometrial cancer (EC) is very much limited. In this commentary, we summarize the main clinicopathologic features of LS-related EC and propose universal screening for LS in individuals with endometrial cancer.
Appendix
Available only for authorised users
Literature
1.
Aaltonen L, Johns L, Jarvinen H, Mecklin JP, Houlston R: Explaining the familial colorectal cancer risk associated with mismatch repair (MMR)-deficient and MMR-stable tumors. Clin Cancer Res. 2007, 13: 356-361. 10.1158/1078-0432.CCR-06-1256.CrossRefPubMed
2.
Lynch HT, de la Chapelle A: Hereditary colorectal cancer. N Engl J Med. 2003, 348: 919-932. 10.1056/NEJMra012242.CrossRefPubMed
3.
Geiersbach KB, Samowitz WS: Microsatellite instability and colorectal cancer. Arch Pathol Lab Med. 2011, 135: 1269-1277. 10.5858/arpa.2011-0035-RA.CrossRefPubMed
4.
Lu KH, Dinh M, Kohlmann W, Watson P, Green J, Syngal S, Bandipalliam P, Chen LM, Allen B, Conrad P, Terdiman J, Sun C, Daniels M, Burke T, Gershenson DM, Lynch H, Lynch P, Broaddus RR: Gynecologic cancer as a “sentinel cancer” for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol. 2005, 105: 569-574. 10.1097/01.AOG.0000154885.44002.ae.CrossRefPubMed
5.
Banno K, Yanokura M, Kobayashi Y, Kawaguchi M, Nomura H, Hirasawa A, Susumu N, Aoki D: Endometrial cancer as a familial tumor: pathology and molecular carcinogenesis (review). Curr Genomics. 2009, 10: 127-132. 10.2174/138920209787847069.PubMedCentralCrossRefPubMed
6.
Bonadona V, Bonaiti B, Olschwang S, Grandjouan S, Huiart L, Longy M, Guimbaud R, Buecher B, Bignon YJ, Caron O, Colas C, Nogues C, Lejeune-Dumoulin S, Olivier-Faivre L, Polycarpe-Osaer F, Nguyen TD, Desseigne F, Saurin JC, Berthet P, Leroux D, Duffour J, Manouvrier S, Frebourg T, Sobol H, Lasset C, Bonaiti-Pellie C: Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA. 2011, 305: 2304-2310. 10.1001/jama.2011.743.CrossRefPubMed
7.
Hampel H, Frankel W, Panescu J, Lockman J, Sotamaa K, Fix D, Comeras I, La Jeunesse J, Nakagawa H, Westman JA, Prior TW, Clendenning M, Penzone P, Lombardi J, Dunn P, Cohn DE, Copeland L, Eaton L, Fowler J, Lewandowski G, Vaccarello L, Bell J, Reid G, de la Chapelle A: Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res. 2006, 66: 7810-7817. 10.1158/0008-5472.CAN-06-1114.CrossRefPubMed
8.
Senter L, Clendenning M, Sotamaa K, Hampel H, Green J, Potter JD, Lindblom A, Lagerstedt K, Thibodeau SN, Lindor NM, Young J, Winship I, Dowty JG, White DM, Hopper JL, Baglietto L, Jenkins MA, de la Chapelle A: The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology. 2008, 135: 419-428. 10.1053/j.gastro.2008.04.026.PubMedCentralCrossRefPubMed
9.
Jass JR, Cottier DS, Jeevaratnam P, Pokos V, Holdaway KM, Bowden ML, Van de Water NS, Browett PJ: Diagnostic use of microsatellite instability in hereditary non-polyposis colorectal cancer. Lancet. 1995, 346: 1200-1201. 10.1016/S0140-6736(95)92902-9.CrossRefPubMed
10.
Peltomaki P: Role of DNA mismatch repair defects in the pathogenesis of human cancer. J Clin Oncol. 2003, 21: 1174-1179. 10.1200/JCO.2003.04.060.CrossRefPubMed
11.
Peltomaki P, Vasen H: Mutations associated with HNPCC predisposition – Update of ICG-HNPCC/INSiGHT mutation database. Dis Markers. 2004, 20: 269-276.PubMedCentralCrossRefPubMed
12.
Hendriks YM, Wagner A, Morreau H, Menko F, Stormorken A, Quehenberger F, Sandkuijl L, Moller P, Genuardi M, Van Houwelingen H, Tops C, Van Puijenbroek M, Verkuijlen P, Kenter G, Van Mil A, Meijers-Heijboer H, Tan GB, Breuning MH, Fodde R, Wijnen JT, Brocker-Vriends AH, Vasen H: Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology. 2004, 127: 17-25. 10.1053/j.gastro.2004.03.068.CrossRefPubMed
13.
Dunlop MG, Farrington SM, Carothers AD, Wyllie AH, Sharp L, Burn J, Liu B, Kinzler KW, Vogelstein B: Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet. 1997, 6: 105-110. 10.1093/hmg/6.1.105.CrossRefPubMed
14.
Aarnio M, Mecklin JP, Aaltonen LA, Nystrom-Lahti M, Jarvinen HJ: Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer. 1995, 64: 430-433. 10.1002/ijc.2910640613.CrossRefPubMed
15.
Lu KH, Schorge JO, Rodabaugh KJ, Daniels MS, Sun CC, Soliman PT, White KG, Luthra R, Gershenson DM, Broaddus RR: Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer. J Clin Oncol. 2007, 25: 5158-5164. 10.1200/JCO.2007.10.8597.CrossRefPubMed
16.
Resnick KE, Hampel H, Fishel R, Cohn DE: Current and emerging trends in Lynch syndrome identification in women with endometrial cancer. Gynecol Oncol. 2009, 114: 128-134. 10.1016/j.ygyno.2009.03.003.PubMedCentralCrossRefPubMed
17.
Hampel H, Panescu J, Lockman J, Sotamaa K, Fix D, Comeras I, LaJeunesse J, Nakagawa H, Westman JA, Prior TW, Clendenning M, de la Chapelle A, Frankel W, Penzone P, Cohn DE, Copeland L, Eaton L, Fowler J, Lombardi J, Dunn P, Bell J, Reid G, Lewandowski G, Vaccarello L: Comment on: Screening for Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) among Endometrial Cancer Patients. Cancer Res. 2007, 67: 9603-10.1158/0008-5472.CAN-07-2308.CrossRefPubMed
18.
Ryan P, Mulligan AM, Aronson M, Ferguson SE, Bapat B, Semotiuk K, Holter S, Kwon J, Kalloger SE, Gilks CB, Gallinger S, Pollett A, Clarke BA: Comparison of clinical schemas and morphologic features in predicting Lynch syndrome in mutation-positive patients with endometrial cancer encountered in the context of familial gastrointestinal cancer registries. Cancer. 2012, 118: 681-688. 10.1002/cncr.26323.CrossRefPubMed
19.
Lu KH, Broaddus RR: Gynecologic Cancers in Lynch Syndrome/HNPCC. Fam Cancer. 2005, 4: 249-254. 10.1007/s10689-005-1838-3.CrossRefPubMed
20.
Soliman PT, Broaddus RR, Schmeler KM, Daniels MS, Gonzalez D, Slomovitz BM, Gershenson DM, Lu KH: Women with synchronous primary cancers of the endometrium and ovary: do they have Lynch syndrome?. J Clin Oncol. 2005, 23: 9344-9350. 10.1200/JCO.2005.03.5915.CrossRefPubMed
21.
Watson P, Vasen HF, Mecklin JP, Bernstein I, Aarnio M, Jarvinen HJ, Myrhoj T, Sunde L, Wijnen JT, Lynch HT: The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer. 2008, 123: 444-449. 10.1002/ijc.23508.PubMedCentralCrossRefPubMed
22.
Lynch HT, Harris RE, Lynch PM, Guirgis HA, Lynch JF, Bardawil WA: Role of heredity in multiple primary cancer. Cancer. 1977, 40: 1849-1854. 10.1002/1097-0142(197710)40:4+<1849::AID-CNCR2820400813>3.0.CO;2-U.CrossRefPubMed
23.
Mecklin JP, Jarvinen HJ: Clinical features of colorectal carcinoma in cancer family syndrome. Dis Colon Rectum. 1986, 29: 160-164. 10.1007/BF02555012.CrossRefPubMed
24.
Carcangiu ML, Radice P, Casalini P, Bertario L, Merola M, Sala P: Lynch syndrome–related endometrial carcinomas show a high frequency of nonendometrioid types and of high FIGO grade endometrioid types. Int J Surg Pathol. 2010, 18: 21-26. 10.1177/1066896909332117.CrossRefPubMed
25.
Broaddus RR, Lynch HT, Chen LM, Daniels MS, Conrad P, Munsell MF, White KG, Luthra R, Lu KH: Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma. Cancer. 2006, 106: 87-94. 10.1002/cncr.21560.CrossRefPubMed
26.
South SA, Hutton M, Farrell C, Mhawech-Fauceglia P, Rodabaugh KJ: Uterine carcinosarcoma associated with hereditary nonpolyposis colorectal cancer. Obstet Gynecol. 2007, 110: 543-545. 10.1097/01.AOG.0000275262.60526.01.CrossRefPubMed
27.
Garg K, Shih K, Barakat R, Zhou Q, Iasonos A, Soslow RA: Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset. Am J Surg Pathol. 2009, 33: 1869-1877. 10.1097/PAS.0b013e3181bc9866.CrossRefPubMed
28.
Christopherson WM, Alberhasky RC, Connelly PJ: Carcinoma of the endometrium. II. Papillary adenocarcinoma: a clinical pathological study, 46 cases. Am J Clin Pathol. 1982, 77: 534-540.PubMed
29.
Balmana J, Stockwell DH, Steyerberg EW, Stoffel EM, Deffenbaugh AM, Reid JE, Ward B, Scholl T, Hendrickson B, Tazelaar J, Burbidge LA, Syngal S: Prediction of MLH1 and MSH2 mutations in Lynch syndrome. JAMA. 2006, 296: 1469-1478. 10.1001/jama.296.12.1469.CrossRefPubMed
30.
Chen S, Wang W, Lee S, Nafa K, Lee J, Romans K, Watson P, Gruber SB, Euhus D, Kinzler KW, Jass J, Gallinger S, Lindor NM, Casey G, Ellis N, Giardiello FM, Offit K, Parmigiani G: Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA. 2006, 296: 1479-1487. 10.1001/jama.296.12.1479.PubMedCentralCrossRefPubMed
31.
Westin SN, Lacour RA, Urbauer DL, Luthra R, Bodurka DC, Lu KH, Broaddus RR: Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome. J Clin Oncol. 2008, 26: 5965-5971. 10.1200/JCO.2008.18.6296.PubMedCentralCrossRefPubMed
32.
Goodfellow PJ, Buttin BM, Herzog TJ, Rader JS, Gibb RK, Swisher E, Look K, Walls KC, Fan MY, Mutch DG: Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. Proc Natl Acad Sci U S A. 2003, 100: 5908-5913. 10.1073/pnas.1030231100.PubMedCentralCrossRefPubMed
33.
Honore LH, Hanson J, Andrew SE: Microsatellite instability in endometrioid endometrial carcinoma: correlation with clinically relevant pathologic variables. Int J Gynecol Cancer. 2006, 16: 1386-1392. 10.1111/j.1525-1438.2006.00535.x.CrossRefPubMed
34.
Boland CR, Fishel R: Lynch syndrome: form, function, proteins, and basketball. Gastroenterology. 2005, 129: 751-755.CrossRefPubMed
35.
Weissman SM, Burt R, Church J, Erdman S, Hampel H, Holter S, Jasperson K, Kalady MF, Haidle JL, Lynch HT, Palaniappan S, Wise PE, Senter L: Identification of individuals at risk for Lynch syndrome using targeted evaluations and genetic testing: National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Colorectal Cancer joint practice guideline. J Genet Couns. 2012, 21: 484-493. 10.1007/s10897-011-9465-7.CrossRefPubMed
36.
Garg K, Leitao MM, Kauff ND, Hansen J, Kosarin K, Shia J, Soslow RA: Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities. Am J Surg Pathol. 2009, 33: 925-933. 10.1097/PAS.0b013e318197a046.CrossRefPubMed
Metadata
Title
Lynch syndrome related endometrial cancer: clinical significance beyond the endometrium
Authors
Yiying Wang
Yue Wang
Jie Li
Janiel Cragun
Kenneth Hatch
Setsuko K Chambers
Wenxin Zheng
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2013
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/1756-8722-6-22

Other articles of this Issue 1/2013

Journal of Hematology & Oncology 1/2013 Go to the issue

Research

Population level survival of patients with chronic myelocytic leukemia in Germany compared to the US in the early 21st century

Letter to the Editor

Leukemic transformation driven by an ASXL1 mutation after a JAK2V617F-positive primary myelofibrosis: clonal evolution and hierarchy revealed by next-generation sequencing

Review

Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges

Research

Early stage follicular lymphoma: what is the clinical impact of the first-line treatment strategy?

Research

Protein biomarkers distinguish between high- and low-risk pediatric acute lymphoblastic leukemia in a tissue specific manner

Research

Stem cell factor SALL4, a potential prognostic marker for myelodysplastic syndromes
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits